Results 301 to 310 of about 326,443 (336)
Domain adaptation, self-supervision, and generative augmentation enhance GNNs for breast cancer prediction. [PDF]
Sci RepQiu S, Zhao Y, Li X.
europepmc +1 more source
Survival analysis of adjuvant endocrine therapy in HER2 positive early breast cancer patients with low ER positivity. [PDF]
Breast Cancer ResYu HH +6 more
europepmc +1 more source
Case Report: Perioperative application of trastuzumab deruxtecan in <i>HER2</i> exon 20 mutation-positive non-small cell lung cancer. [PDF]
Front PharmacolLi W +5 more
europepmc +1 more source
Durable clinical and metabolic response to Trastuzumab Deruxtecan in heavily Pretreated male HER2-low metastatic breast cancer: a case report. [PDF]
Oxf Med Case ReportsLamsyah O +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer
British Journal of Cancer, 2023This study aimed to elucidate the clinicopathological and molecular features of HER2-amplified and HER2-low colorectal cancers (CRCs). We also characterised HER2 expression statuses in CRCs focusing on their intratumoral heterogeneity and alterations in metastatic lesions to establish practical HER2 status assessment.We evaluated 1009 CRCs for HER2 ...
Taiki Hashimoto +12 more
openaire +2 more sources
Loss of HER2 after HER2-targeted treatment
Breast Cancer Research and Treatment, 2019HER2 expression has been reported to be discordant between primary tumor and metastatic tissue.HER2 discordance and relation to HER2-targeted treatment was investigated in 227 patients with primary breast cancer.HER2 discordance between primary biopsy and second biopsy after neoadjuvant or adjuvant treatment was observed in 20.7%.
Tanja Ignatov +4 more
openaire +2 more sources
Truncated HER2: implications for HER2-targeted therapeutics
Drug Discovery Today, 2011The HER2 receptor is currently one of the flagship therapeutic targets in clinical oncology. Trastuzumab, an antibody targeting HER2, has become a foundation of care in women with HER2-positive breast cancer. However, many women with metastatic breast cancer do not respond to trastuzumab-based therapy.
Radoslaw, Zagozdzon +2 more
openaire +3 more sources
Der Pathologe, 2020
A prerequisite for all HER2 directed therapies is the demonstration of HER2 receptor protein overexpression and/or gene amplification by in situ hybridization (ISH). ASCO and CAP have published several HER2 test guidelines over the past 15 years for both breast and gastric cancer. The latest version for breast cancer (2018) focuses on special issues of
Josef, Rüschoff +3 more
openaire +3 more sources
A prerequisite for all HER2 directed therapies is the demonstration of HER2 receptor protein overexpression and/or gene amplification by in situ hybridization (ISH). ASCO and CAP have published several HER2 test guidelines over the past 15 years for both breast and gastric cancer. The latest version for breast cancer (2018) focuses on special issues of
Josef, Rüschoff +3 more
openaire +3 more sources
Seminars in Oncology, 2002
HER2/neu is a compelling cancer vaccine candidate because it is overexpressed on some cancer cells relative to normal tissues, it is known to be immunogenic in both animal models and in humans, and it is already known to be targetable by the antibody component of the immune system in the form of monoclonal antibody therapy with trastuzumab.
Teresa M, Foy +5 more
openaire +2 more sources
HER2/neu is a compelling cancer vaccine candidate because it is overexpressed on some cancer cells relative to normal tissues, it is known to be immunogenic in both animal models and in humans, and it is already known to be targetable by the antibody component of the immune system in the form of monoclonal antibody therapy with trastuzumab.
Teresa M, Foy +5 more
openaire +2 more sources
Seminars in Oncology, 2006
Variable expression of the HER2 receptor has been implicated in the pathogenesis of a number of malignancies. Many therapeutic modalities have been devised that target the receptor and downstream molecular pathways. The humanized monoclonal antibodies trastuzumab and pertuzumab bind epitopes on the extracellular domain, resulting in cell growth ...
Sumanta Kumar, Pal, Mark, Pegram
openaire +2 more sources
Variable expression of the HER2 receptor has been implicated in the pathogenesis of a number of malignancies. Many therapeutic modalities have been devised that target the receptor and downstream molecular pathways. The humanized monoclonal antibodies trastuzumab and pertuzumab bind epitopes on the extracellular domain, resulting in cell growth ...
Sumanta Kumar, Pal, Mark, Pegram
openaire +2 more sources